ABH Angel Biotech

TIDMABH

RNS Number : 5192H

Angel Biotechnology Holdings Plc

12 July 2012

For immediate release 12 July 2012

Angel Biotechnology Holdings plc

("Angel" or "the Company")

Result of Annual General Meeting

Angel Biotechnology Holdings plc, (AIM:ABH), the biopharmaceutical contract manufacturer, announces that at the Company's Annual General Meeting held today, all resolutions were duly passed.

For further information:

Angel Biotechnology Holdings plc

Lorna Peers, Finance Director +44 (0) 131 445 6077

Stewart White, Acting CEO/Commercial Director www.angelbio.com

Grant Thornton, Corporate Finance

Colin Aaronson / Melanie Frean +44 (0) 20 7383 5100

Hybridan LLP (Broker)

Claire Noyce / Deepak Reddy +44 (0) 20 7947 4350

Media enquiries:

The Communications Portfolio Ltd

Ariane Comstive / Caolan Mahon +44 (0) 20 7536 2028 / 2029

ariane.comstive@communications-portfolio.co.uk

Notes to Editors:

Angel Biotechnology Holdings plc is a full service contract bio-manufacturing partner to biotechnology and pharmaceutical companies worldwide. Angel specializes in advanced biologics including biopharmaceutical proteins and cell therapies, such as cellular vaccines and stem cells. At present, Angel's products are principally used in pre-clinical studies and clinical trials with a view to becoming the contract manufacturer of choice on a continuing basis.

Drug development companies outsource their biopharmaceutical manufacturing requirements to Angel to reduce their own capital requirements and enable them to develop products more rapidly. In addition, Angel provides complete regulatory services and documentation to its customers while its manufacturing processes adhere to the most stringent regulatory requirements. Products are produced to current Good Manufacturing Practice (cGMP) standards as required by the US Food and Drug Administration (FDA), and in facilities that are certified to European standards by the Medicines and Healthcare products Regulatory Agency (MHRA).

Its customers range from early-stage biotechnology companies including ReNeuron plc and US-based Pathfinder Cell Therapy, to established pharmaceutical companies such as Russian-based Materia Medica Holdings.

Angel has three facilities: Pentlands Science Park near Edinburgh where it employs 38 people, a site in Cramlington, near Newcastle-upon-Tyne, which is expected to employ up to 10 people by the end of 2012 and Angel Biomedical Ltd facility in Glasgow.

More information is available at www.angelbio.com .

- Ends -

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGBKBDNCBKKOOD

Angel Biotechnology (LSE:ABH)
Historical Stock Chart
From Apr 2024 to May 2024

Angel Biotechnology (LSE:ABH)
Historical Stock Chart
From May 2023 to May 2024